Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas

Daniel P. Nussbaum, Paul J. Speicher, Brian C. Gulack, Asvin M. Ganapathi, Brian R. Englum, David G. Kirsch, Douglas Tyler, Dan G. Blazer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: To evaluate long-term survival among patients undergoing radiation therapy (RT), followed by surgical resection of retroperitoneal sarcomas (RPS). Background: Despite a lack of level 1 evidence supporting neoadjuvant RT for RPS, its use has increased substantially over the past decade. Methods: The 1998-2011 National Cancer Data Base was queried to identify patients who underwent resection of RPS. Subjects were grouped by use of neoadjuvant RT. Perioperative variables and outcomes were compared. Multivariable logistic regression was performed to assess predictors of neoadjuvant RT. Groups were propensity matched using a 2:1 nearest neighbor algorithm and short-termoutcomeswere compared. Finally, long-termsurvivalwas evaluated using the Kaplan-Meier method,with comparisons based on the log-rank test. Results: A total of 11,324 patients were identified. Neoadjuvant RT was administered to 696 patients (6.1%). During the study period, preoperative RT use increased from 4% to nearly 15%. Male sex, tumor size larger than 5 cm, treatment at an academic/research program, and higher tumor grade all predicted neoadjuvant RT administration. After propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chemotherapy. Although neoadjuvant RT was associated with a higher rate of negative margins (77.5% vs 73.0%; P = 0.014), there was no corresponding improvement in 5-year survival (53.2% vs 54.2%; P = 0.695). Conclusions: Despite the increasing use of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality remains unclear. Continued investigation is needed to better define the role of RT among patients with RPS.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalAnnals of Surgery
Volume262
Issue number1
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Sarcoma
Radiotherapy
Survival
Neoplasms
Logistic Models
Databases
Drug Therapy

Keywords

  • Neoadjuvant
  • Preoperative
  • Radiation therapy
  • Radiotherapy
  • Retroperitoneal sarcoma
  • Sarcoma

ASJC Scopus subject areas

  • Surgery

Cite this

Nussbaum, D. P., Speicher, P. J., Gulack, B. C., Ganapathi, A. M., Englum, B. R., Kirsch, D. G., ... Blazer, D. G. (2015). Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas. Annals of Surgery, 262(1), 163-170. https://doi.org/10.1097/SLA.0000000000000840

Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas. / Nussbaum, Daniel P.; Speicher, Paul J.; Gulack, Brian C.; Ganapathi, Asvin M.; Englum, Brian R.; Kirsch, David G.; Tyler, Douglas; Blazer, Dan G.

In: Annals of Surgery, Vol. 262, No. 1, 01.07.2015, p. 163-170.

Research output: Contribution to journalArticle

Nussbaum, DP, Speicher, PJ, Gulack, BC, Ganapathi, AM, Englum, BR, Kirsch, DG, Tyler, D & Blazer, DG 2015, 'Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas', Annals of Surgery, vol. 262, no. 1, pp. 163-170. https://doi.org/10.1097/SLA.0000000000000840
Nussbaum DP, Speicher PJ, Gulack BC, Ganapathi AM, Englum BR, Kirsch DG et al. Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas. Annals of Surgery. 2015 Jul 1;262(1):163-170. https://doi.org/10.1097/SLA.0000000000000840
Nussbaum, Daniel P. ; Speicher, Paul J. ; Gulack, Brian C. ; Ganapathi, Asvin M. ; Englum, Brian R. ; Kirsch, David G. ; Tyler, Douglas ; Blazer, Dan G. / Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas. In: Annals of Surgery. 2015 ; Vol. 262, No. 1. pp. 163-170.
@article{82bbe0c8b9604d14bf3a9784f04d8833,
title = "Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas",
abstract = "Objective: To evaluate long-term survival among patients undergoing radiation therapy (RT), followed by surgical resection of retroperitoneal sarcomas (RPS). Background: Despite a lack of level 1 evidence supporting neoadjuvant RT for RPS, its use has increased substantially over the past decade. Methods: The 1998-2011 National Cancer Data Base was queried to identify patients who underwent resection of RPS. Subjects were grouped by use of neoadjuvant RT. Perioperative variables and outcomes were compared. Multivariable logistic regression was performed to assess predictors of neoadjuvant RT. Groups were propensity matched using a 2:1 nearest neighbor algorithm and short-termoutcomeswere compared. Finally, long-termsurvivalwas evaluated using the Kaplan-Meier method,with comparisons based on the log-rank test. Results: A total of 11,324 patients were identified. Neoadjuvant RT was administered to 696 patients (6.1{\%}). During the study period, preoperative RT use increased from 4{\%} to nearly 15{\%}. Male sex, tumor size larger than 5 cm, treatment at an academic/research program, and higher tumor grade all predicted neoadjuvant RT administration. After propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chemotherapy. Although neoadjuvant RT was associated with a higher rate of negative margins (77.5{\%} vs 73.0{\%}; P = 0.014), there was no corresponding improvement in 5-year survival (53.2{\%} vs 54.2{\%}; P = 0.695). Conclusions: Despite the increasing use of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality remains unclear. Continued investigation is needed to better define the role of RT among patients with RPS.",
keywords = "Neoadjuvant, Preoperative, Radiation therapy, Radiotherapy, Retroperitoneal sarcoma, Sarcoma",
author = "Nussbaum, {Daniel P.} and Speicher, {Paul J.} and Gulack, {Brian C.} and Ganapathi, {Asvin M.} and Englum, {Brian R.} and Kirsch, {David G.} and Douglas Tyler and Blazer, {Dan G.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1097/SLA.0000000000000840",
language = "English (US)",
volume = "262",
pages = "163--170",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas

AU - Nussbaum, Daniel P.

AU - Speicher, Paul J.

AU - Gulack, Brian C.

AU - Ganapathi, Asvin M.

AU - Englum, Brian R.

AU - Kirsch, David G.

AU - Tyler, Douglas

AU - Blazer, Dan G.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective: To evaluate long-term survival among patients undergoing radiation therapy (RT), followed by surgical resection of retroperitoneal sarcomas (RPS). Background: Despite a lack of level 1 evidence supporting neoadjuvant RT for RPS, its use has increased substantially over the past decade. Methods: The 1998-2011 National Cancer Data Base was queried to identify patients who underwent resection of RPS. Subjects were grouped by use of neoadjuvant RT. Perioperative variables and outcomes were compared. Multivariable logistic regression was performed to assess predictors of neoadjuvant RT. Groups were propensity matched using a 2:1 nearest neighbor algorithm and short-termoutcomeswere compared. Finally, long-termsurvivalwas evaluated using the Kaplan-Meier method,with comparisons based on the log-rank test. Results: A total of 11,324 patients were identified. Neoadjuvant RT was administered to 696 patients (6.1%). During the study period, preoperative RT use increased from 4% to nearly 15%. Male sex, tumor size larger than 5 cm, treatment at an academic/research program, and higher tumor grade all predicted neoadjuvant RT administration. After propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chemotherapy. Although neoadjuvant RT was associated with a higher rate of negative margins (77.5% vs 73.0%; P = 0.014), there was no corresponding improvement in 5-year survival (53.2% vs 54.2%; P = 0.695). Conclusions: Despite the increasing use of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality remains unclear. Continued investigation is needed to better define the role of RT among patients with RPS.

AB - Objective: To evaluate long-term survival among patients undergoing radiation therapy (RT), followed by surgical resection of retroperitoneal sarcomas (RPS). Background: Despite a lack of level 1 evidence supporting neoadjuvant RT for RPS, its use has increased substantially over the past decade. Methods: The 1998-2011 National Cancer Data Base was queried to identify patients who underwent resection of RPS. Subjects were grouped by use of neoadjuvant RT. Perioperative variables and outcomes were compared. Multivariable logistic regression was performed to assess predictors of neoadjuvant RT. Groups were propensity matched using a 2:1 nearest neighbor algorithm and short-termoutcomeswere compared. Finally, long-termsurvivalwas evaluated using the Kaplan-Meier method,with comparisons based on the log-rank test. Results: A total of 11,324 patients were identified. Neoadjuvant RT was administered to 696 patients (6.1%). During the study period, preoperative RT use increased from 4% to nearly 15%. Male sex, tumor size larger than 5 cm, treatment at an academic/research program, and higher tumor grade all predicted neoadjuvant RT administration. After propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chemotherapy. Although neoadjuvant RT was associated with a higher rate of negative margins (77.5% vs 73.0%; P = 0.014), there was no corresponding improvement in 5-year survival (53.2% vs 54.2%; P = 0.695). Conclusions: Despite the increasing use of neoadjuvant RT for patients with RPS, the survival benefit associated with this treatment modality remains unclear. Continued investigation is needed to better define the role of RT among patients with RPS.

KW - Neoadjuvant

KW - Preoperative

KW - Radiation therapy

KW - Radiotherapy

KW - Retroperitoneal sarcoma

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84942522804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942522804&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000000840

DO - 10.1097/SLA.0000000000000840

M3 - Article

VL - 262

SP - 163

EP - 170

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 1

ER -